Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
Abroad (travel likely)RecruitingPHASE3
Conditions
Relapsed Small Cell Lung Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Jilin Provincial Tumor Hospital, Jilin City, China
Contact: Study coordinator (Chunjiao Wu)
Study leads
Ying Chen, Doctor
Principal Investigator
Jilin Provincial Tumor Hospital